Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

16.46 -0.13 (-0.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?
Viatris has been on fire lately. In the past six months alone, the company’s stock price has rocketed 58.2%, reaching $16.13 per share. This was partly thank... 
Via StockStory
News headline image
This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why? ↗
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Stock Under $50 to Target This Week and 2 We Avoid
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call
Viatris delivered a positive first quarter, outperforming Wall Street’s expectations on both revenue and non-GAAP earnings per share. Management attributed t... 
Via StockStory
Topics Earnings
Viatris (NASDAQ:VTRS) Shares Rise as Q1 Earnings Top Estimates ↗
Via Chartmill
Viatris Inc (NASDAQ:VTRS) Beats Q4 2025 Estimates and Completes Strategic Review ↗
Via Chartmill
News headline image
3 Unprofitable Stocks That Fall Short
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance
Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 8.1% year on year to $3.52 bill... 
Via StockStory
News headline image
Viatris (VTRS) Q1 2026 Earnings Transcript ↗
Viatris (VTRS) Q1 2026 Earnings Transcript 
Via The Motley Fool
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue
Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $3.52 bil... 
Via StockStory
Topics Artificial Intelligence
News headline image
Earnings To Watch: Viatris (VTRS) Reports Q1 Results Tomorrow
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy Government Stocks
News headline image
QSM Asset Management Loads Up 611,000 Mobileye Shares ↗
Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers. 
Via The Motley Fool
Topics Economy Regulatory Compliance Supply Chain
News headline image
A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗
Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗
ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗
Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry. 
Via The Motley Fool
News headline image
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?
Viatris has had an impressive run over the past six months as its shares have beaten the S&P 500 by 34.7%. The stock now trades at $14.11, marking a 37.8% ga... 
Via StockStory
Topics Stocks
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceu... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bastion Bets on Government Spending with $8 Million New Stake in Parsons ↗
Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond. 
Via The Motley Fool
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of... 
Via StockStory
News headline image
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect. 
Via StockStory
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.